U.S., Jan. 29 -- ClinicalTrials.gov registry received information related to the study (NCT06797375) titled 'Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of RLYB116 in Healthy Participants' on Jan. 22.
Brief Summary: This study will investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of RLYB116 (with an improved impurity profile) following repeated administration of RLYB116 in healthy participants.
Study Start Date: March, 2025
Study Type: INTERVENTIONAL
Condition:
Hematologic Diseases
Autoimmune Diseases
Intervention:
DRUG: RLYB116 for Injection
RLYB116 is a small protein composed of an Affibody(R) Z-domain that binds with high affinity to C5, inhibiting terminal complement act...